TransEnterix Lags Rivals in Key Metrics

Surgical robotics firm faces headwinds compared to competitors

Published on Feb. 28, 2026

Got story updates? Submit your updates here. ›

A new analysis shows that TransEnterix, a medical device company focused on robotic surgical systems, is underperforming its industry rivals across several key financial and operational metrics. The company trails its peers in areas like net margins, return on equity, and return on assets, and its stock price is also more volatile than the industry average.

Why it matters

As a relatively young player in the growing surgical robotics market, TransEnterix's struggles to match its competitors on profitability and other measures could hinder its ability to gain market share and attract investment. The findings raise questions about the company's long-term viability and competitiveness within the highly competitive medical devices industry.

The details

TransEnterix has a net margin of -2,149.15%, return on equity of -83.74%, and return on assets of -64.94%, all of which lag behind its rivals' averages. The company's stock also exhibits higher volatility, with a beta of 2.56 compared to 1.76 for the industry. Additionally, TransEnterix has lower institutional and insider ownership levels than its peers.

  • The data analyzed covers the period up to February 20, 2026.

The players

TransEnterix, Inc.

A medical device company that develops and sells robotic surgical systems, primarily the Senhance System in Europe.

Surgical, Medical, And Dental Instruments And Supplies Industry

The broader industry group that TransEnterix competes within, which includes the company's rivals.

Got photos? Submit your photos here. ›

The takeaway

TransEnterix's struggles to match the financial performance and operational efficiency of its competitors in the surgical robotics space raise concerns about the company's long-term viability and ability to gain ground in this fast-growing market. The findings underscore the intense competition and challenges facing newer entrants in the highly competitive medical devices industry.